Study S001598

Effects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05780905
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 50
Start: 2024-01-11
Primary completion: 2026-03-31
Lead sponsor: University of Washington
Conditions: Diabetes Mellitus, Type 2; Stroke (CVA) or Transient Ischemic Attack
Interventions: DRUG:Semaglutide Auto-Injector; OTHER:Placebo
Results posted: FALSE
Secondary identifiers: OTHER_GRANT:U1111-1271-3352

Registered primary outcomes

Intracranial blood flow (IBF) [Approximately 12 Months]
bloodbrain barrier Ktrans [Approximately 12 Months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.